Introduction & Objective: This study aimed to determine the real-world effectiveness of injectable semaglutide once weekly (sema OW) on weight and HbA1c outcomes among people with type 2 diabetes (T2D) in the US.
Methods: This observational cohort study involved adults with uncontrolled T2D (HbA1c ≥7%) initiating sema OW from January 2018—February 2022 (first prescription = index) using IQVIA PharMetrics® Plus and Ambulatory Electronic Medical Records databases. Change in weight, BMI and HbA1c outcomes from baseline to 1-year post-index were descriptively compared overall, as well as for subgroups of those persistent (≤60-day gap in treatment, subgroup 1), those receiving maintenance dose ≥1 mg (subgroup 2), and those who were persistent and receiving dose ≥1 mg (subgroup 3).
Results: Among the final sample (n=772) and all subgroups, a significant mean change from baseline was seen in weight, BMI and HbA1c (all p<0.0001; Fig.). Mean changes in weight and BMI were numerically greatest in subgroup 3 (Fig.). The proportion of patients with obesity (BMI ≥30 kg/m2) significantly decreased from 84.0% at baseline to 77.1% post-index (p<0.0001).
Conclusion: Adults with T2D initiating sema OW had statistically significant decreases in weight, BMI and HbA1c after 1 year, with better weight outcomes in patients persistent to treatment and receiving maintenance dose ≥1 mg.
J. Amamoo: None. R.P. Doshi: None. J. Noone: Employee; Novo Nordisk. L. Xie: None. C.L. Gamble: Employee; Novo Nordisk. M. Guevarra: Stock/Shareholder; Novo Nordisk. V. Divino: Employee; IQVIA Inc. J. Chen: None. A.A. King: Speaker's Bureau; Abbott, MannKind Corporation, Novo Nordisk. Advisory Panel; Novo Nordisk. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Dexcom, Inc. Speaker's Bureau; Astellas Pharma Inc.
Novo Nordisk
